News
Drugs
PBM Transparency
October 4, 2018
|
PBM transparency, or lack thereof, has long been an issue among payers and policymakers. PBMs’ multiple revenue sources and confusing pricing and packaging methods leave many employers unsure of what bundled services they’re really paying for.
U.S. Drug Spending Climbs
June 7, 2016
|
The Wall Street Journal reported that, according to IMS Health research, total spending on prescription drugs in the U.S. rose 12.2% to nearly $425 billion in 2015, fueled by the introduction of expensive new drugs for cancer and infections, as well as price hikes for older drugs.